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Plain Language Summary
Health Technology Assessment (HTA) is an evidence-based decision-making process,
focusing on evaluating health technologies for funding within a healthcare system.
‘Health technologies’ include medications, medical devices, diagnostics, medical
procedures and services. Health Technology Assessment international (HTAi) is a
global society for those who produce, use, participate in, or encounter HTA. The
HTAi Secretariat supports special interest groups within HTAi. One such special
interest group, the Patient and Citizen Involvement in HTA Interest Group (PCIG),
focuses on strengthening patient involvement in HTA. PCIG’s members are from HTA
agencies, research, industry, and patient organisations. We describe the steps PCIG
has taken to form an international panel of patient advocates (the Patient Panel) as
an autonomous group within its governance structure that reports directly to the
PCIG Steering Committee. The Patient Panel was established in order to strengthen
meaningful patient involvement in HTA by working co-productively with other PCIG
members to develop resources accessible to patient organisations.
Patient advocates known to be active within HTA in their own countries were invited
to form the inaugural group, with one person appointed to chair the group for the first
year. Documentation had been prepared to inform potential members and set out
potential roles as seen by the Steering Committee. The appointed Patient Panel is
defining its own terms of reference, goals and objectives. The Panel Chair is a member
of the PCIG Steering Committee, and is mentored by the retiring PCIG chair. A registry
of activities is part of monitoring and evaluation.
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Abstract
Background Health Technology Assessment (HTA) is an evidence-based decision-
making process, focusing on evaluating health technologies for funding within a
healthcare system or medical insurance system. ‘Health technologies’ are understood
broadly, and include medications, medical devices, diagnostics, medical procedures and
services. Health Technology Assessment international (HTAi) is a global society for those
who produce, use, participate in, or encounter HTA. The HTAi Secretariat supports
special interest groups within HTAi, including the Patient and Citizen Involvement in
HTA Interest Group (PCIG), which focuses on strengthening patient involvement in HTA.
PCIG’s members come from HTA agencies, research, industry, and patient organisations.
Main body We describe the steps the PCIG has taken to form an international panel of
patient advocates as an autonomous group within its governance structure, reporting
directly to the PCIG Steering Committee. Patient advocates known to be active within
HTA in their own countries were invited to form the inaugural group. One person was
invited to chair the Panel for the first year of its operation, based on the candidate’s
experience of working across diseases and countries, and being new to HTAi.
Documentation was prepared to inform potential members of the Panel and set out
potential roles as seen by the Steering Committee. The Panel came into being in March
2016 and is now setting out its own working principles, goals and objectives. The Panel
Chair is a member of the PCIG Steering Committee, and is mentored by the previous
PCIG chair. A registry of activities has been set up as part of monitoring and evaluation.
The Patient Panel is intended to provide a focus within the PCIG for patient advocates
to work among themselves and co-productively through the PCIG Working Groups to
develop mutual understanding and strengthen meaningful patient involvement in HTA
internationally. Patient advocates can benefit from a clear understanding the evidence
requirements within HTA and how information can be effectively presented by patient
groups to decision-making bodies.
Conclusion The HTAi Patient and Citizen Involvement Interest Group has set up a
Patient Panel consisting of patient advocates. The intent is to work co-productively to
advance patient involvement in HTA.
Keywords: Patient involvement, Patient engagement, Patient and citizen involvement
interest group, Health technology assessment, Co-production, Evaluation
Background
Health Technology Assessment (HTA) is an evidence-based decision-making process,
focusing on evaluating health technologies for funding within a healthcare system or
medical insurance system. HTA is formally defined as “the systematic evaluation of the
clinical effectiveness and/or cost-effectiveness and/or the social and ethical impact of a
health technology on the lives of patients and the health care system” [1]. ‘Health tech-
nologies’ are understood broadly, and include medications, medical devices, diagnostics,
medical procedures and services.
Health Technology Assessment international, or HTAi, is the international society
for the promotion of HTA as a means of informing evidence-based healthcare
decision making. HTAi’s mission is to support and promote the development,
communication, understanding and use of HTA around the world as a
scientifically-based means of promoting the introduction of effective innovations
and the effective use of resources in health care [2]. HTAi also serves as an
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umbrella organisation for interest groups focused on specific aspects of HTA, such
as ethics, hospital-based HTA, HTA in developing countries, and patient and citi-
zen involvement [3].
The Patient and Citizen Involvement in HTA Interest Group (PCIG) is the focus of
the present commentary, in particular the process and outcome of PCIG’s initiative to
set up a Patient Panel within its governance structure. By sharing our process and its
outcome we aim both to attract interest in the Panel and to assist other groups endea-
vouring to establish similar panels.
HTAi collects annual membership dues from its members, and organises annual meet-
ings for which it seeks both public and industry sponsorship. Reduced membership fees
are paid by patient advocates, although at present it is possible to join the PCIG without
becoming an HTAi member. In order to encourage participation in the annual meetings,
patient advocates and delegates from low and low-middle income countries have the op-
portunity to apply for travel grants, made available by HTAi. Some funding is also annu-
ally distributed by HTAi among the interest groups, including PCIG. In recent years,
PCIG has sought funding from the HTAi Board to enable a yearly face-to-face meeting to
further its work; this covers at least some of the participants’ expenses. Other funding for
PCIG’s activities has come from grants from industry for specific projects, and in 2016
from the Pharmaceutical Research and Manufacturers of America (PhRMA) through the
HTAi Secretariat. However, the bulk of the work within the PCIG, including as members
of PCIG working groups and the PCIG Steering Committee, is carried out in members’
own time and is unpaid by HTAi. The interest groups provide an annual report to the
HTAi Board, including details on expenditures. The chairs of the interest groups are part
of an HTAi Board-led steering committee as a mechanism to provide accountability on
the part of the interest groups and the Board.
Main text
The Patient and Citizen Involvement in HTA Interest Group
The Patient and Citizen Involvement in HTA Interest Group (PCIG) was established in
2005. The overarching aim of the PCIG is to enhance the quality and relevance of HTA
through patient and citizen involvement [4]. The PCIG objectives are to: either pro-
mote or develop robust methodologies to incorporate patient perspectives in HTA, and
share good practices in patient and public involvement in HTA processes; strengthen
HTA by systematic incorporation of patient perspectives; support countries with
limited experience with HTA and incorporating patient and citizen perspectives; and
demonstrate the value and impact of patient and public engagement in HTA.
PCIG’s membership consists of over 250 individuals from HTA agencies, industry,
patient advocates, researchers and others who are interested in or working with
patients and caregivers who seek access to healthcare interventions through formal
mechanisms such as HTA. Members are linked through a monthly e-bulletin, and have
the opportunity to convene at an annual business meeting held during HTAi annual
meetings, as well as to participate in workshops and panel sessions held at this event.
PCIG is organised into three working groups (see Fig. 1) and members can volunteer
to participate in a working group that is aligned to their particular interests. The objec-
tives of the Methods and Impact Working Group are to identify robust evidence that
can impact on HTA decision making about the views and preferences of patients. It
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aims to share information about research methodologies and research findings and
build an evidence base for the impact of patient involvement in HTA. The Patient
Involvement and Education Working Group seeks to promote knowledge, skills
and opportunities for meaningful patient involvement in HTA activities in coun-
tries in all regions of the world. The Citizen and Community Involvement Working
Group concentrates on the role of public or citizen and community involvement in
HTA. The members of all three working groups collaborate on projects both
within and across working groups, develop materials and resources, and identify
gaps in current knowledge around patient and citizen involvement in HTA. Some
of these projects have included: the Values and Quality Standards for patient in-
volvement in HTA, generic templates for patient group submissions to HTA agen-
cies, guidance on making submissions, ethics guidance for patient organisations,
and frequently asked questions [4, 5].
The structure and work of the PCIG is overseen by a Steering Committee. The
Steering Committee’s remit is to oversee the governance and activities of the PCIG,
including coordination of the overall strategy, promotion of the outputs of the
Interest Group, and reporting back to the HTAi Board through the Chair. The
Steering Committee consists of 12 members who are researchers, people working
with patient and public involvement in HTA agencies, independent consultants, a
patient organisation (European Patients’ Forum) representative, and patient advo-
cates. It was the Steering Committee that saw the need to strengthen the voices of
patient advocates in the work of the PCIG by forming an international group of
patient advocates with experience in HTA. This could be done in a focused and
collaborative way by following the concepts of person-centred health care, in that a
health system is there to meet the needs of patients.
Fig. 1 Organisational structure of the HTAi Patient and Citizen Involvement in HTA Interest
Group (PCIG)
Wale et al. Research Involvement and Engagement  (2017) 3:3 Page 4 of 10
Principles followed by the Patient and Citizen Involvement in HTA Interest Group
As part of its work, the PCIG has developed a set of values or principles to be upheld
in the involvement of patients and the public in HTA processes, together with quality
standards [6]. The values are as follows:
 Relevance: Patients have knowledge, perspectives and experiences that are unique
and contribute to essential evidence for HTA.
 Fairness: Patients have the same rights to contribute as other stakeholders and have
access to processes that enable effective engagement.
 Equity: Patient involvement contributes to equity by seeking to understand the
diverse needs of patients with a particular health issue, balanced against the
requirements of a health system that seeks to distribute resources fairly.
 Legitimacy: Patient involvement facilitates those affected by the HTA
recommendations or decisions to participate; contributing to the transparency,
accountability and credibility of the decision-making process.
 Capacity building: Patient involvement processes address barriers to involving
patients and build capacity for patients and HTA organizations to work together.
These values are directed at HTA agencies and have been acknowledged, referenced
and where applicable translated by HTA agencies in England, Scotland, France,
Belgium, Colombia and Canada [7]. They are also applicable to the Patient Panel and
underpin its ability to function effectively within the PCIG.
Patient-centeredness
In May 2014, the World Health Organization approved a resolution urging member
states to establish and utilise health technology assessment processes in support of uni-
versal health coverage [8]. Inclusion of patient perspectives in the HTA process can
therefore be seen as a means of supporting and ensuring universal access to healthcare
interventions that are needed, appropriate, and accepted by patients for their care [8].
Some countries have directed their efforts toward patient-focused HTA, in line with
the principles of person-centred health care that advocate shared decision making, self-
management, and patient empowerment [9, 10]. England, Scotland, and Canada, for ex-
ample, have established mechanisms for the involvement of patients and the public in
their HTA processes, at The National Institute for Health and Care Excellence (NICE),
Scottish Medicines Consortium (SMC), and the Canadian Agency for Drugs and
Technologies in Health (CADTH), respectively.
In line with health systems that embrace patient involvement in health care and
health policy, as well as with its own set of principles, the PCIG has restructured to be
more inclusive of patient advocates and to set up a Patient Panel. The Panel is intended
to provide patient advocates and their patient organisations a stronger voice in the gov-
ernance and activities of the Interest Group.
Setting up the HTAi Patient Panel
The possibility of establishing an international group of patient advocates within the
PCIG was first raised in 2015, by the then Chair (JW). This concept was raised with
Wale et al. Research Involvement and Engagement  (2017) 3:3 Page 5 of 10
the PCIG Steering Committee (SC) as a means of achieving a more democratic and effect-
ive way of operating the PCIG. It was modelled on the advisory group of regulators that
has been set up to provide regulatory support to another interest group within HTAi, the
HTA-Regulatory Interactions Interest Group. The model of a multi-stakeholder patient
involvement interest group that incorporates a definable group of patient advocates to
give them a well-defined voice was therefore adopted from within HTAi itself, rather than
from other international organisations in HTA. It differs from the International Society
for Pharmacoeconomics and Outcomes Research (ISPOR) model of a Patient Centred
Special Interest Group and its Patient Engagement in Research Working Group that
involves patient advocates and other HTA stakeholders in clinical outcomes research
[11, 12]. The Steering Committee recognised the advantage of having a defined group
of patient advocates working within the PCIG and therefore making valuable contri-
butions to the work of the PCIG, following the principle of ‘together we are stronger’.
It was necessary to prepare documents for potential Panel members, with informa-
tion on HTA, HTAi, the PCIG itself, as well as on the envisioned roles for the potential
members of the Patient Panel [13].
The Chair of the Patient Panel was to become a member of the PCIG SC; and the Pa-
tient Panel was to sit alongside the SC (see Fig. 1). Establishing the Patient Panel re-
quired revision of the Terms of Reference of the SC, as well as a strengthening of the
process for declaration of interests. The latter was done to improve transparency about
membership of the Interest Group. These changes were approved by the Interest
Group members at its 2016 Annual Business Meeting.
Identification of potential members of the Patient Panel was undertaken by the then
Chair, herself a patient advocate, and the other Steering Committee members. PCIG
were looking for a balanced group of patient advocates in the area of HTA who were
held in high esteem by their colleagues, and international representation. One of the
considerations around asking patient advocates to become involved is that they are
busy individuals with high demands on their time, and HTAi is not the only inter-
national not-for-profit organisation working in this space – others include, for example,
ISPOR and Develop Innovate Advance (DIA), which are also actively involved in the
European public-private Innovative Medicines Initiative (IMI) funded European Pa-
tients Academy on Therapeutic Innovation (EUPATI). However, the PCIG has shown
itself to be effective as a group in working with patient advocates and others to develop
a library of resources that are widely used, as previously described. We were able to
send out formal invitations to potential Panel members, and the Patient Panel was fina-
lised in March 2016, with members of the PCIG formally notified in the same month.
The Chair of the Patient Panel was identified after careful consideration of the compos-
ition of the Panel. The key considerations were that: the candidate be knowledgeable in
the area of HTA, has experience in working with people from patient support groups
across a range of diseases and from different countries, and that they were new to the
PCIG. The Patient Panel Chair is being mentored by the now previous chair of the
PCIG, and provided with secretarial support, to ensure that they are supported as they
take up this collaborative role. Although the inaugural Chair of the Patient Panel was
identified by the SC, and appointed for an initial period of one year, it is envisioned
that the Panel will subsequently appoint its own chair. The Chair is a member of
the Steering Committee of the PCIG under the new PCIG SC Terms of Reference.
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Already the international Patient Panel is becoming familiar with the work of
the HTAi, PCIG and their members, and is exploring ways in which its efforts
can be mutually beneficial. The first face-to-face interactions took place at the
HTAi annual conference in June 2016, in Tokyo, where the Patient Panel actively
contributed by commenting on the clarity of the website for the event in terms
of who the HTAi stakeholders actually are; providing background material [14];
presenting at the PCIG full-day workshop ‘East Meets West: what we can learn
from each other about patient perspectives and adding value to HTA and policy
decision making’; providing input into a Policy Forum Panel presentation; and
attending the 2016 Annual Business Meeting. It also contributed to the 2016
PCIG Working Groups’ annual face-to-face meeting. Panel members are particu-
larly interested in learning from each other and from the PCIG about how
patient involvement in HTA in their own countries can be built on and im-
proved, and upskilling in cross-border collaboration on HTA, for example in the
European Union.
Identified roles of the Patient Panel
The Patient Panel is intended to be a collaborative and supportive ‘forum’ of patient ad-
vocates, developing discussions to address the purpose, processes, facilitators and bar-
riers for patient and public involvement in a range of countries. To this end, it is
envisioned that the Patient Panel members will collaborate with other PCIG members
to strengthen methodologies for capturing patient perspectives in HTA. They will de-
velop their own goals and objectives. Until then, the Patient Panel’s key roles, as identi-
fied by the SC, include:
 providing a strong representation of patient views alongside those of the views of
other stakeholders within the PCIG;
 enabling a supportive environment for patient advocates as valued stakeholders;
 acting as a sounding board for new PCIG projects and contributing ideas, assessing
their relevance and practicality for patient organisations;
 developing their own projects through broad discussions.
It needs to be emphasised that the Patient Panel will devise its own work plan, prior-
ities and terms of reference. A registry of activities has been initiated to facilitate an
evaluation of their activities within the PCIG.
Patient Panel membership
Currently, a core group of nine international patient advocates with experience in con-
tributing to HTA processes in their own countries form the Patient Panel. This number
is anticipated to grow as the Panel becomes more established. The current members
come from one international organisation and six national organisations, in England,
Scotland, Netherlands, Canada, Taiwan, and Australia. Because the Panel is self-
governing, it can broaden its membership to add strengths and to encompass more
countries.
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Moving forward
The impetus for forming the Patient Panel came from within the HTAi PCIG Steering
Committee, who sought patient advocates with HTA experience, the potential to make
a valuable contribution to the Panel, and who were willing and committed to be part of
the Panel. International diversity was a key consideration. The SC designed a structural
framework for the Patient Panel while leaving details on how it would operate and the
principles under which it would function up to the Panel and its Chair to develop, with
approval by the SC. The Patient Panel have had one teleconference, in September 2016,
to begin discussions on these.
Some of the Patient Panel members attended the HTAi Annual Meeting in May
2016 and contributed to the PCIG one-day workshop. The Chair and two of the
Patient Panel were able to attend the face-to-face meeting of the PCIG Working
Groups in October 2016. Members who were present confirmed that the Panel is
needed within the PCIG, as a source of patient opinions. Members value being
involved in Working Group discussions as well as having the opportunity to have
their own discussions and to share experiences. Each member belongs to a patient
organisation and has access to other patient groups, so has the capacity to consult
widely. The Patient Panel Chair stated that membership is based on the skills of
the group (rather than country ‘representation’). It is important that they are
accessible to each other and the PCIG, and that they feel empowered to provide
input, even if not asked. The terminology is often unclear in HTA such that a
common language is needed for communication and upskilling relevant to HTA.
Many patients and patient organisations are not aware of HTA and its function.
HTA also needs to be transparent and patient input and its impact made visible.
Conflicts of interest need to be managed. The Patient Panel will be part of the
solution to these issues by working collaboratively with PCIG and HTAi.
The Patient Panel needs to identify best strategies for communicating with the
PCIG and, at the same time, how to be of most value to the patient community. It
can also undertake to lead on better relationships between patient organisations
and HTA agencies, outside of the formal relationships within agency advisory
groups.
Challenges
The Patient Panel, as with the PCIG, has members from different countries. As with many
international organisations, English is the language spoken within HTAi but is a second
language for many people, which may present communication challenges. The structure
of health systems and their culture also vary globally, and the role of patient advocates
within the health systems. The PCIG has members from different stakeholder groups
within HTA – including industry, researchers, decisions-makers, patients – who may have
different perspectives on patient involvement in HTA. Furthermore, the PCIG, including
the Patient Panel, has a limited budget, relying largely on goodwill to achieve its goals.
Funding limits the ability to attend face-to-face meetings and much of its work is done
through e-mail and teleconferencing using facilities provided by the HTAi Secretariat.
However, face-to-face meetings occur at the HTAi Annual Meetings and in the second
quarter of the year for Working Groups and now the Patient Panel.
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Conclusions
We describe here the initiative, the process, and the outcome of establishing a Patient
Panel within the HTAi Patient and Citizen Involvement in HTA Interest Group. Al-
though the Panel is still in its early stages, it will considerably strengthen and enrich
the work of the PCIG, in addition to being consistent with the PCIG’s own values and
the increasing emphasis on patient-centeredness in health systems around the world.
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